{"id":"NCT03306277","sponsor":"Novartis Gene Therapies","briefTitle":"Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1","officialTitle":"Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-24","primaryCompletion":"2019-11-12","completion":"2019-11-12","firstPosted":"2017-10-11","resultsPosted":"2020-07-16","lastUpdate":"2022-08-16"},"enrollment":22,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["SMA - Spinal Muscular Atrophy","Gene Therapy"],"interventions":[{"type":"BIOLOGICAL","name":"Onasemnogene Abeparvovec-xioi","otherNames":["Zolgensma"]}],"arms":[{"label":"Onasemnogene Abeparvovec-xioi","type":"EXPERIMENTAL"}],"summary":"Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.","primaryOutcome":{"measure":"Achievement of Independent Sitting for at Least 30 Seconds","timeFrame":"Up to 18 months","effectByArm":[{"arm":"Onasemnogene Abeparvovec-xioi","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["34383289","33743238"],"seeAlso":["http://AveXis.com","https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17657"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":22},"commonTop":["Pyrexia","Upper respiratory tract infection","Constipation","Scoliosis","Cough"]}}